Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- umbralisib
- Zejula (niraparib)
Interactions between your drugs
niraparib umbralisib
Applies to: Zejula (niraparib), umbralisib
Using niraparib together with umbralisib may have additive effects on the immune system, possibly increasing the risk of low blood cell counts (e.G., red blood cells, white blood cells, platelets) and infections. Less commonly, the risk of more serious side effects known as myelodysplastic syndrome or acute myeloid leukemia could increase. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Let your doctor know if you experience pale skin, weakness, fatigue, fever, weight loss, infections, shortness of breath, unusual bleeding or bruising, or blood in urine or stool. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
umbralisib food
Applies to: umbralisib
Food helps with the absorption of umbralisib into the blood stream. You should take this medication with food at approximately the same time each day.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Epkinly
Epkinly is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ...
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Brukinsa
Brukinsa is used to treat adults with mantle cell lymphoma, Waldenström’s macroglobulinemia, ma ...
Ruxience
Ruxience is a biosimilar to Rituxan and is used to treat certain leukemias and lymphomas and some ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Gazyva
Gazyva is used to treat chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL) in adults ...
Obinutuzumab
Obinutuzumab is used to treat chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL) in ...
Zanubrutinib
Zanubrutinib is a targeted treatment that may be used to treat adults with chronic lymphocytic ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.